Ipilimumab

證據等級: L5

預測適應症: 2 個

Ipilimumab: From Cutaneous Melanoma to Non-Cutaneous Melanoma

One-Sentence Summary

Ipilimumab is an anti-CTLA-4 monoclonal antibody that has become a standard immunotherapy option for advanced melanoma. The TxGNN model additionally predicts activity in Non-Cutaneous Melanoma (uveal, mucosal, acral subtypes), supported by ~60 registered clinical trials and 5 publications in the evidence pack. A second, much weaker signal for Choroideremia was also generated by the model but shows no biological plausibility and is flagged for Hold.

Quick Overview

Item	Content
Original Indication	Not provided in this Evidence Pack (no BfArM/regulatory license data available); publicly known clinical use is advanced/metastatic cutaneous melanoma
Predicted New Indication	Non-Cutaneous Melanoma (uveal, mucosal, acral subtypes)
TxGNN Prediction Score	99.02% (rank 9967)
Evidence Level	L2
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available from DrugBank for this candidate (Data Gap, item DG002). Based on known information, ipilimumab is an anti-CTLA-4 monoclonal antibody that blocks the inhibitory CTLA-4 checkpoint on T cells, thereby restoring and amplifying anti-tumor T-cell activation. Its efficacy in cutaneous melanoma has been established across multiple Phase 3 programs, and mechanistically this checkpoint-blockade approach is not restricted to a specific melanoma subtype — the underlying immune-activation mechanism should, in principle, be equally applicable to non-cutaneous melanoma.

Cutaneous and non-cutaneous melanoma (uveal, mucosal, acral) share a common cell of origin (melanocytes) and are all treated within the same immuno-oncology paradigm. However, non-cutaneous subtypes typically carry a lower tumor mutational burden (TMB) than UV-driven cutaneous melanoma, which historically correlates with reduced response rates to checkpoint inhibitors. Several trials in the evidence pack (e.g., NCT03165422, NCT03369223) include broader melanoma populations or real-world use after other checkpoint inhibitors, providing indirect but relevant support, while dedicated non-cutaneous-subtype stratified data remain limited — this is reflected in the L2 evidence level and the "Proceed with Guardrails" recommendation rather than an outright "Go."

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02506153	Phase 3	Active, not recruiting	1301	Large adjuvant trial comparing interferon/ipilimumab choice vs. pembrolizumab in high-risk resected melanoma; not yet completed, not subtype-restricted.
NCT03369223	Phase 1/2	Completed	356	BMS-986249 ± nivolumab in advanced solid tumors including melanoma; provides safety/efficacy signal for checkpoint-combination approaches.
NCT03165422	N/A (real-world)	Completed	68	Japanese real-world chart review of ipilimumab after nivolumab failure in melanoma; supports clinical feasibility across melanoma populations.
NCT01621490	Phase 1	Completed	170	Biomarker/pharmacodynamic study of nivolumab ± ipilimumab in advanced (unresectable/metastatic) melanoma.
NCT02115139	Phase 2	Completed	58	Radiation + ipilimumab in melanoma with brain metastases; showed added clinical benefit from ipilimumab combined with radiotherapy.
NCT01689974	Phase 2	Terminated	10	Ipilimumab ± radiotherapy in metastatic melanoma; terminated early, underpowered.
NCT06240143	Phase 1/2	Recruiting	96	Neoadjuvant intradermal ipilimumab + nivolumab in high-risk Stage II melanoma; no results yet.
NCT02210104	Phase 1	Withdrawn	0	CD4+ NY-ESO-1-specific T cells + ipilimumab; withdrawn, no data.
NCT04021420	Phase 1/2	Unknown	21	Blood-brain barrier opening device + nivolumab ± ipilimumab in melanoma brain metastases; status unknown.
NCT06880198	N/A	Recruiting	20	Non-pharmacological supportive-care intervention alongside anti-PD-1 ± ipilimumab regimens; not a direct efficacy trial.

Note: The evidence pack contains ~60 registered trials in total; the table above lists the 10 trials with an assigned relevance grade (Grade B/C). Most trials evaluate ipilimumab broadly in advanced/metastatic melanoma rather than non-cutaneous subtypes specifically — this subtype-specificity gap is the main limitation supporting an L2 (rather than L1) evidence level.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24999899	2014	Cohort/Retrospective	The Medical Journal of Australia	Evaluated ipilimumab efficacy/tolerability in pretreated cutaneous, uveal, and mucosal melanoma; directly assessed the association between response and melanoma subtype.
28183255	2018	Review	Current Cancer Drug Targets	Systematic review of melanoma adjuvant treatment (2000–2015 trials); notes only ~5% of melanomas are non-cutaneous and reviews adjuvant options including checkpoint inhibitors.
37887546	2023	Cohort	Current Oncology (Toronto)	Retrospective multi-center comparison of anti-PD-1 monotherapy vs. combination with ipilimumab by age group in advanced melanoma; supports combination efficacy across broad melanoma populations.
29466692	2018	Review	Discovery Medicine	Clinical update on anti-PD-1 antibodies alone or combined with ipilimumab as frontline therapy for advanced melanoma, including BRAF-wild-type and BRAF-mutated disease.
40236344	2025	Case Report	Cureus	Case of colonic metastasis from melanoma treated with systemic immunotherapy including ipilimumab-class agents; illustrates real-world use and GI-related irAE risk.

Germany Market Information

Ipilimumab is currently not marketed in Germany under this Evidence Pack (market_status: 未上市), with 0 authorizations on record. No license entries were available to extract dosage form or approved indication text.

Cytotoxicity (Antineoplastic Drugs)

Ipilimumab is classified here as antineoplastic based on its established clinical use in advanced/metastatic melanoma treatment and its mechanism as an immune checkpoint inhibitor.

Item	Content
Cytotoxicity Classification	Immunotherapy (immune checkpoint inhibitor; anti-CTLA-4 monoclonal antibody) — not a conventional cytotoxic chemotherapeutic
Myelosuppression Risk	Low — checkpoint inhibitors are not typically myelosuppressive; the dominant toxicity concern is immune-related adverse events (irAEs) rather than bone marrow suppression
Emetogenicity Classification	Low — immunotherapies generally carry minimal intrinsic emetogenic potential
Monitoring Items	Liver function tests, thyroid function, adrenal/cortisol function, GI symptoms (colitis/diarrhea screening), skin reactions, and CBC as part of irAE surveillance
Handling Protection	As a biologic monoclonal antibody, ipilimumab does not require traditional cytotoxic-drug handling precautions; institutional biologic-agent handling protocols should still be followed

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data were available in this Evidence Pack (item DG001, flagged as Blocking for S1 safety assessment).

Additional TxGNN Prediction (Flagged Low-Confidence)

The model's top-ranked prediction (score 99.06%) was Choroideremia, a monogenic retinal degenerative disease caused by CHM gene mutations/REP1 protein deficiency. This has no clinical trials, no literature, and no known mechanistic link to CTLA-4 blockade. The evidence pack itself flags this as a likely embedding-proximity artifact rather than a genuine mechanistic association (evidence level L5, decision stage S0, recommendation Hold). This prediction is not carried forward for further evaluation and is noted here only for transparency.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for non-cutaneous melanoma indication)

Rationale: Ipilimumab's mechanism and broad melanoma trial base provide plausible support for use in non-cutaneous melanoma subtypes, but subtype-specific stratified efficacy data are limited and the drug is currently unmarketed in Germany with a blocking safety-data gap.

To proceed, the following is needed:

TFDA/BfArM package insert data (warnings, contraindications) — currently a Blocking gap (DG001)
Detailed mechanism-of-action data from DrugBank (DG002)
Subtype-stratified (uveal/mucosal/acral) response and survival data specific to non-cutaneous melanoma
Regulatory pathway assessment given current "not marketed" status in Germany
irAE-specific safety monitoring plan given absence of current safety/DDI data

The Choroideremia signal requires no further action (Hold; no biological rationale, no supporting evidence).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.